PE20160753A1 - Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 - Google Patents

Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Info

Publication number
PE20160753A1
PE20160753A1 PE2016000675A PE2016000675A PE20160753A1 PE 20160753 A1 PE20160753 A1 PE 20160753A1 PE 2016000675 A PE2016000675 A PE 2016000675A PE 2016000675 A PE2016000675 A PE 2016000675A PE 20160753 A1 PE20160753 A1 PE 20160753A1
Authority
PE
Peru
Prior art keywords
agonist
combined therapy
ang2 antibody
antibody
ang2
Prior art date
Application number
PE2016000675A
Other languages
English (en)
Inventor
Christian Klein
Alfred Zippelius
Markus Thomas
Philipp Mueller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160753A1 publication Critical patent/PE20160753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a la terapia combinada de un anticuerpo que se une a angiopoyetina humana 2 (ANG-2) con un agonista de CD40 para tratar diversos tipos de cancer o para retrasar la progresion de un tumor
PE2016000675A 2013-12-20 2014-12-17 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 PE20160753A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198753 2013-12-20
EP14158331 2014-03-07

Publications (1)

Publication Number Publication Date
PE20160753A1 true PE20160753A1 (es) 2016-08-01

Family

ID=52278610

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000675A PE20160753A1 (es) 2013-12-20 2014-12-17 Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40

Country Status (20)

Country Link
US (3) US20150232548A1 (es)
EP (1) EP3082857B1 (es)
JP (1) JP6345787B2 (es)
KR (1) KR20160085888A (es)
CN (1) CN105611944A (es)
AU (1) AU2014368695A1 (es)
BR (1) BR112016007112A2 (es)
CA (1) CA2923591A1 (es)
CL (1) CL2016001586A1 (es)
CR (1) CR20160199A (es)
EA (1) EA201600474A1 (es)
HK (1) HK1221409A1 (es)
IL (1) IL244454A0 (es)
MX (1) MX2016008099A (es)
PE (1) PE20160753A1 (es)
PH (1) PH12016500482A1 (es)
SG (1) SG11201604594SA (es)
TW (1) TWI559931B (es)
WO (1) WO2015091655A1 (es)
ZA (1) ZA201601895B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA47472A (fr) 2014-08-12 2019-12-18 Alligator Bioscience Ab Anticorps
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
KR20170082594A (ko) * 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
AU2016285913B2 (en) 2015-06-29 2022-06-16 Bristol-Myers Squibb Company Antibodies to CD40
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
AR113862A1 (es) * 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
KR102527315B1 (ko) * 2019-02-25 2023-05-03 주식회사 파멥신 항-Ang2 항체 및 이의 용도
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
CN112168960A (zh) * 2019-07-03 2021-01-05 义慧科技(深圳)有限公司 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma

Also Published As

Publication number Publication date
EA201600474A1 (ru) 2016-11-30
MX2016008099A (es) 2016-10-13
TWI559931B (en) 2016-12-01
SG11201604594SA (en) 2016-07-28
US20150232548A1 (en) 2015-08-20
JP2017504600A (ja) 2017-02-09
CN105611944A (zh) 2016-05-25
ZA201601895B (en) 2018-11-28
WO2015091655A1 (en) 2015-06-25
PH12016500482A1 (en) 2016-05-16
US20180134780A1 (en) 2018-05-17
BR112016007112A2 (pt) 2017-09-19
EP3082857A1 (en) 2016-10-26
KR20160085888A (ko) 2016-07-18
CR20160199A (es) 2016-06-17
EP3082857B1 (en) 2018-07-25
CA2923591A1 (en) 2015-06-25
AU2014368695A1 (en) 2016-04-14
IL244454A0 (en) 2016-04-21
TW201526915A (zh) 2015-07-16
CL2016001586A1 (es) 2017-05-12
US20200199215A1 (en) 2020-06-25
JP6345787B2 (ja) 2018-06-20
HK1221409A1 (zh) 2017-06-02

Similar Documents

Publication Publication Date Title
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2019000061A1 (es) Anticuerpo para anti-claudin 18a2 y su utilización.
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CO2017013332A2 (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
EA201792546A1 (ru) Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2016002017A1 (es) Inhibición dirigida del factor de crecimiento transformador b (tgfb).
AR101697A1 (es) Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana
BR112016000903A2 (pt) anticorpos
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
UY35399A (es) Conjugados de fármacos con anticuerpos
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
EP3609575A4 (en) PHOTOBIOMODULATION THERAPY TO REDUCE THE EFFECTS OF FIBROMYALGIA
SV2019005822A (es) Metodos para tratar el cáncer de próstata
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal